Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

Key Points

• Most patients with drug-resistant extramedullary myeloma responded to talquetamab plus teclistamab, indicating a potential treatment strategy.
• The incidence of adverse events of grade 3 or above was found to be high, aligning with prior studies of each drug alone.
• Observational analysis of extramedullary myeloma cases revealed significant responses to the combined treatment approach.
• High adverse events reinforce the need for careful monitoring when using talquetamab and teclistamab together.